GlaxoSmithKline (GSK.L: Quote) is assessing final bids for a clutch of its non-prescription drugs, keeping the process on track for the selection of a buyer by the end of the year, people familiar with the matter said on Monday. “The final, second-round bids are in. The deadline was the end of last week,” said one source. Private equity firms have dominated the process, with Bain Capital and Blackstone (BX.N: Quote), which has partnered with Prestige Brands (PBH.N: Quote), seen as the two front-runners.
